Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of Low-Level Laser Therapy on the Serum TGF-beta 1 Concentrations in Individuals with Autoimmune Thyroiditis

Full text
Author(s):
Hoefling, Danilo B. [1, 2] ; Chavantes, Maria Cristina [2] ; Acencio, Milena M. P. [3] ; Cerri, Giovanni G. [1] ; Marui, Suemi [4] ; Yoshimura, Elisabeth M. [5] ; Chammas, Maria Cristina [1]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Sch Med, Hosp Clin, Dept Radiol, Ultrasound Unit, BR-05403001 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Sch Med, Hosp Clin, Laser Med Ctr, Heart Inst, BR-05403001 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Sch Med, Hosp Clin, Div Pulm, Pleura Lab, Heart Inst, BR-05403001 Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Sch Med, Hosp Clin, Discipline Endocrinol & Metab, Dept Clin Med, Thyro, BR-05403001 Sao Paulo, SP - Brazil
[5] Univ Sao Paulo, Dept Nucl Phys, Inst Phys, BR-05403001 Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Photomedicine and Laser Surgery; v. 32, n. 8, p. 444-449, AUG 2014.
Web of Science Citations: 5
Abstract

Objective: The objective of this study was to evaluate the serum concentration of transforming growth factor-beta 1 (TGF-beta 1) after low-level laser therapy (LLLT) in patients with hypothyroidism resulting from chronic autoimmune thyroiditis (CAT). Background data: Certain data indicate that LLLT is effective in patients with hypothyroidism caused by CAT; however, the mechanisms of action of LLLT in thyroid tissue are unknown. Cytokines could play a role in the response to LLLT. Methods: A randomized, placebo-controlled trial included 43 patients with a history of levothyroxine therapy for CAT-induced hypothyroidism. The patients were randomly assigned to receive either 10 sessions of LLLT (830 nm, 50 mW output power, and 707 J/cm(2) fluence; L group, n = 23) or 10 sessions of a placebo treatment (P group, n = 20) twice a week. Levothyroxine was maintained at the same dose during the entire study period. TGF-beta 1 was measured both pre-intervention and 30 days post-intervention in both groups. The differences were calculated between the TGF-beta 1 values observed 30 days post-intervention and the pre-intervention TGF-beta 1 values for each group (intragroup). Results: Comparing the differences in TGF-beta 1 levels between the L group (874.9 +/- 541.7 pg/mL) and the P group (-128.4 +/- 832.8 pg/mL) revealed that there was a statistically significant increase in TGF-beta 1 levels 30 days post-intervention in group L compared with the placebo group (p = 0.0379). Conclusions: This finding suggested that the significant increase in serum TGF-beta 1 levels in patients with CAT-induced hypothyroidism was associated with the thyroid LLLT procedure. Future studies of the effect of LLLT on TGF-beta 1 gene expression in thyroid tissue are necessary to confirm these findings. (AU)